479 related articles for article (PubMed ID: 30990042)
1. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
[TBL] [Abstract][Full Text] [Related]
2. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
Hu B; Hu J
Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
[TBL] [Abstract][Full Text] [Related]
3. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
4. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
6. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
7. Discovery of
Chen Z; Hu B; Rej RK; Wu D; Acharyya RK; Wang M; Xu T; Lu J; Metwally H; Wang Y; McEachern D; Bai L; Gersch CL; Wang M; Zhang W; Li Q; Wen B; Sun D; Rae JM; Wang S
J Med Chem; 2023 Sep; 66(17):12559-12585. PubMed ID: 37647546
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
[TBL] [Abstract][Full Text] [Related]
9. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
[TBL] [Abstract][Full Text] [Related]
11. Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen.
Loren G; Espuny I; Llorente A; Donoghue C; Verdaguer X; Gomis RR; Riera A
Eur J Med Chem; 2022 Dec; 243():114770. PubMed ID: 36148710
[TBL] [Abstract][Full Text] [Related]
12. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
14. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
15. Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD).
Dong J; Wang TL; Lu J; Ding CZ; Hu L; Hu G; He H; Zeng X; Li X; Sun D; Zhu Y; Shen L; Gu Q; Chan CC; Xia Y; Li J; Chen S
Bioorg Med Chem Lett; 2020 Nov; 30(22):127601. PubMed ID: 33035677
[TBL] [Abstract][Full Text] [Related]
16. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
[TBL] [Abstract][Full Text] [Related]
17. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
Liu Q; Tu G; Hu Y; Jiang Q; Liu J; Lin S; Yu Z; Li G; Wu X; Tang Y; Huang X; Xu J; Liu Y; Wu L
Eur J Med Chem; 2022 Jan; 228():114013. PubMed ID: 34864330
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
Xin L; Wang C; Cheng Y; Wang H; Guo X; Deng X; Deng X; Xie B; Hu H; Min C; Dong C; Zhou HB
J Med Chem; 2024 Jun; 67(11):8913-8931. PubMed ID: 38809993
[TBL] [Abstract][Full Text] [Related]
19. Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
Cao C; Yang J; Chen Y; Zhou P; Wang Y; Du W; Zhao L; Chen Y
J Med Chem; 2020 Oct; 63(19):11012-11033. PubMed ID: 32924477
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.
Ragab MA; Elagawany M; Daabees H; Ahmed AF; Awad EM; Billon C; Elgendy B; Abouzid KAM; Kassab SE
Bioorg Chem; 2022 Feb; 119():105554. PubMed ID: 34923243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
